CervoMed (CRVO) Net Cash Flow (2010 - 2026)
CervoMed (CRVO) posted Net Cash Flow of -$293718.0 for Q1 2026, up 75.56% sequentially from -$1.2 million in Q4 2025, and down 119.55% YoY from $1.5 million in Q1 2025.
CervoMed (CRVO) Net Cash Flow (2010 - 2026) Analysis & Trends
CervoMed has reported Net Cash Flow for 17 years, with the latest figure at -$293718.0 in Q1 2026.
- Quarterly Net Cash Flow fell 119.55% year-over-year to -$293718.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.6 million (up 93.95% YoY) and the FY2025 annual result came in at -$764027.0, down 163.32% from the prior year.
- Net Cash Flow improved to -$293718.0 in Q1 2026 per CRVO's latest filing, from -$1.2 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $10.2 million in Q3 2022 and troughed at -$42.8 million in Q2 2024.
- A 5-year average of -$3.4 million and a median of -$1.2 million in 2025 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Net Cash Flow soared 444.21% in 2022, then sank 273.17% in 2024.
- Over 5 years, Net Cash Flow stood at $6.3 million in 2022, then tumbled by 141.73% to -$2.6 million in 2023, then surged by 147.72% to $1.3 million in 2024, then plunged by 195.71% to -$1.2 million in 2025, then surged by 75.56% to -$293718.0 in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$293718.0, -$1.2 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | CervoMed | 26.64 Mn | 26.64 Mn | - | 14.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.52 Mn |
| Jun 30, 2026 | 14.52 Mn |
| Mar 31, 2026 | -293,718.00 |
| Mar 31, 2026 | -293,718.00 |
| Dec 31, 2025 | -1.20 Mn |
| Dec 31, 2025 | -1.20 Mn |
| Sep 30, 2025 | 1.12 Mn |
| Sep 30, 2025 | 1.12 Mn |
| Jun 30, 2025 | -2.18 Mn |
| Jun 30, 2025 | -2.18 Mn |
| Mar 31, 2025 | 1.50 Mn |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2024 | -2.27 Mn |
| Sep 30, 2024 | -2.27 Mn |
| Jun 30, 2024 | -42.77 Mn |
| Jun 30, 2024 | -42.77 Mn |
| Mar 31, 2024 | -1.42 Mn |
| Mar 31, 2024 | -1.42 Mn |